Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 4/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.50 |
| ▸ | NPY2R | P49146 | 3/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025663 | 0.93 | LNPEP (0.59) | LNPEPERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL31710294 | 0.93 | LNPEP (0.59) | LNPEPERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL29972888 | 0.91 | MMP2 (0.52) | LNPEPERAP2 | |
| SCHEMBL29868753 | 0.91 | LNPEP (0.55) | LNPEPERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL25627390 | 0.88 | CHRND (0.50) | NPY4RNPY1RNPY2RNPY5RNAALAD2 | |
| SCHEMBL30688840 | 0.87 | GHSR (0.51) | LNPEPERAP2 | |
| SCHEMBL30090915 | 0.87 | LNPEP (0.64) | LNPEPERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL285712 | 0.86 | NAALAD2 (0.58) | LNPEPERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL29854734 | 0.86 | NAALAD2 (0.58) | LNPEPERAP2NPY4RNPY1RNPY2R | |
| SCHEMBL31710009 | 0.86 | NAALAD2 (0.58) | LNPEPERAP2NPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676599-A1 | IMPROVED BISPECIFIC ANTI-TUMOR ANTIGEN/ANTI-HSG ANTIBODIES FOR PRE-TARGETING OF HYPERPROLIFERATIVE DISORDERS | OncoOne Research & Development GmbH (AT) | 2026-01-14 | — | — | EP | disclosed |
| EP-4396227-B1 | IMPROVED FC SILENCED ANTI-OXMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | ONCOONE RES & DEVELOPMENT GMBH (AT) | 2025-07-09 | — | — | EP | disclosed |
| US-20250129148-A1 | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | ONCOONE RESEARCH & DEVELOPMENT GMBH (AT) | 2025-04-24 | — | — | US | disclosed |
| WO-2024184171-A1 | IMPROVED BISPECIFIC ANTI-TUMOR ANTIGEN/ANTI-HSG ANTIBODIES FOR PRE-TARGETING OF HYPERPROLIFERATIVE DISORDERS | ONCOONE RESEARCH & DEVELOPMENT GMBH (AT) | 2024-09-12 | — | — | WO | disclosed |
| EP-4396227-A1 | IMPROVED FC SILENCED ANTI-OXMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | OncoOne Research & Development GmbH (AT) | 2024-07-10 | — | — | EP | disclosed |
| CN-118302444-A | Improved Fc-silenced anti-oxMIF antibodies with reduced aggregation potential and reduced hydrophobicity | 翁科奥内研发有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023031397-A1 | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | ONCOONE RESEARCH & DEVELOPMENT GMBH (AT) | 2023-03-09 | — | — | WO | disclosed |